8-KExhibits & Filings

ELI LILLY & Co 8-K Report, Exhibit Filing (Jan 5, 2016)

Filed January 5, 2016For Securities:LLY

Summary

Eli Lilly and Company (LLY) filed an 8-K on January 5, 2016, to provide updated financial guidance for 2015 and to announce its financial guidance for the upcoming year, 2016. The company also held a teleconference for analysts and media to discuss these financial projections. This filing is significant as it offers investors insight into management's expectations for the company's financial performance in the near term, allowing for informed investment decisions. A key aspect of this announcement is Lilly's continued use of non-GAAP financial measures. The company emphasizes that these measures, which exclude items such as the impact of acquisitions/divestitures and amortization of intangibles, are provided to help investors better evaluate ongoing operations and identify underlying business trends. While these non-GAAP figures are presented as supplementary, investors are advised to consider them alongside GAAP measures.

Key Highlights

  • 1Eli Lilly announced its financial guidance for 2016 and provided an update on its 2015 financial outlook.
  • 2The company held a teleconference on January 5, 2016, to discuss these financial projections with analysts and media.
  • 3Lilly utilizes non-GAAP financial measures, such as non-GAAP earnings per share, in its reporting.
  • 4Non-GAAP measures exclude impacts from acquisitions, divestitures, and amortization of intangibles to provide a clearer view of ongoing operations.
  • 5Management believes these non-GAAP measures are useful for investors in evaluating performance, making comparisons, and identifying operating trends.
  • 6Prospective financial guidance is subject to adjustments for future matters, similar to those excluded in non-GAAP measures.
  • 7The information provided in Item 2.02 is furnished and not deemed filed under Section 18 of the Exchange Act.

Frequently Asked Questions

The main purpose of this 8-K filing is to provide investors with Eli Lilly's financial guidance for the year 2016 and an update on its financial expectations for 2015. It also announces that the company held a teleconference to discuss these financial projections.

Eli Lilly uses non-GAAP financial measures, such as non-GAAP earnings per share, which differ from standard GAAP measures. They exclude certain items like the impact of acquisitions and divestitures, and amortization of intangibles. Lilly uses these measures to provide investors with a clearer view of its ongoing operations, facilitate meaningful period-over-period comparisons, and help identify operating trends that might otherwise be obscured by these excluded items.

Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, financial performance measures prepared in accordance with GAAP. The company believes these measures offer valuable insights into operational performance and trends.

No, the financial guidance is subject to adjustments for certain future matters, similar to the items excluded in their non-GAAP reporting, for which prospective quantification is often not feasible. This means actual results may differ from the guidance provided.